AIM ImmunoTech Stock Set to Split on Friday, January 9th (NYSEAMERICAN:AIM)

AIM ImmunoTech Inc. (NYSEAMERICAN:AIM) shares are going to split on Friday, January 9th. The 1001-1000 split was recently announced. The newly minted shares will be payable to shareholders after the market closes on Thursday, January 8th.

AIM ImmunoTech Trading Up 5.3%

Shares of NYSEAMERICAN:AIM opened at $1.19 on Monday. AIM ImmunoTech has a 12-month low of $1.07 and a 12-month high of $36.00. The business’s fifty day simple moving average is $1.53 and its 200-day simple moving average is $3.47. The company has a market capitalization of $3.39 million, a PE ratio of -0.06 and a beta of 1.21.

AIM ImmunoTech (NYSEAMERICAN:AIM) last released its quarterly earnings results on Monday, November 17th. The company reported ($1.57) EPS for the quarter. The firm had revenue of $0.03 million during the quarter. Research analysts predict that AIM ImmunoTech will post -0.3 EPS for the current year.

Analyst Ratings Changes

Separately, Zacks Research downgraded shares of AIM ImmunoTech from a “strong-buy” rating to a “hold” rating in a research report on Monday, December 1st. One analyst has rated the stock with a Strong Buy rating and one has given a Hold rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Buy”.

Institutional Trading of AIM ImmunoTech

A hedge fund recently bought a new stake in AIM ImmunoTech stock. Corient Private Wealth LLC acquired a new position in shares of AIM ImmunoTech Inc. (NYSEAMERICAN:AIM) in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 10,001 shares of the company’s stock, valued at approximately $87,000. Corient Private Wealth LLC owned 1.31% of AIM ImmunoTech at the end of the most recent quarter. 12.02% of the stock is owned by institutional investors.

About AIM ImmunoTech

AIM ImmunoTech is a clinical-stage biotechnology company focused on the development and commercialization of immune-modulating therapies for the treatment of viral infections and cancer. The company’s lead product candidate, Ampligen (rintatolimod), is a proprietary toll-like receptor 3 (TLR3) agonist that aims to enhance the body’s innate immune response. AIM ImmunoTech’s research and development efforts center on demonstrating the safety and efficacy of Ampligen as both a standalone therapy and in combination with other treatments.

In addition to its oncology and antiviral programs, the company is advancing clinical trials of Ampligen in patients with chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) and exploring potential applications for emerging viral threats.